Targets › CDK2
13 programs from 11 companies in 18 trials: 11 Phase 1, 5 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, SUV39H1, EZH2. (UniProt, P24941)
Open in Phaseline: the race on CDK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group | TQB3616 capsule CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 3 | HR-positive, HER2-negative Breast Neoplasms; Breast Cancer; Metastatic Breast Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Dinaciclib Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 5 inhibitor | CDK1, CDK2, CDK5, CDK9 | Phase 2 | Acral Lentiginous Melanoma; Advanced Malignant Solid Neoplasm | Mar 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Culmerciclib CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 2 | HR+/HER2- Early Breast Cancer | May 2028 |
| Fudan University | Culmerciclib CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 2 | Breast Cancer | Jun 2028 |
| Sun Yat-sen University | Culmerciclib CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 2 | Breast Cancer | Dec 2028 |
| AstraZeneca | AZD8421 CDK2 inhibitor | CDK2 | Phase 1 | ER+ HER2- Advanced Breast Cancer | Jun 2027 |
| Incyclix Bio | INX-315 CDK2 inhibitor | CDK2 | Phase 1 | Breast Cancer | Jul 2027 |
| NiKang Therapeutics | NKT5097 CDK2/CDK4 dual degrader | CDK2, CDK4 | Phase 1 | HR+ Breast Cancer | Jul 2027 |
| BeiGene | BG-68501 Cyclin-dependent kinase-2 inhibitor | CDK2 | Phase 1 | Breast Cancer | Aug 2027 |
| Eilean Therapeutics | ZE94-0605 Selective cyclin-dependent kinase 2 (CDK2) inhibitor | CDK2 | Phase 1 | Advanced Solid Tumor Cancer | Jan 2028 |
| Avenzo Therapeutics | AVZO-021 CDK2 inhibitor | CDK2 | Phase 1 | Advanced Solid Tumor; HR+/HER2- Breast Cancer | Jan 2028 |
| National Cancer Institute (NCI) | Zotiraciclib Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor | CDK1, CDK2, CDK7, CDK9, FLT3 | Phase 1 | Brain Tumor | Aug 2028 |
| NiKang Therapeutics | NKT3964 CDK2 Degrader | CDK2 | Phase 1 | Solid Tumor | Jan 2029 |
Breast Cancer (6) Brain Tumor (1) HR+/HER2- Early Breast Cancer (1) Advanced Solid Tumor (1) HR+/HER2- Breast Cancer (1) HR-positive, HER2-negative Breast Neoplasms (1) Metastatic Breast Cancer (1) Solid Tumor (1) ER+ HER2- Advanced Breast Cancer (1) Acral Lentiginous Melanoma (1) Advanced Malignant Solid Neoplasm (1) Advanced Solid Tumor Cancer (1)
small molecule (12), mixed (1)
National Cancer Institute (NCI) (2) NiKang Therapeutics (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Avenzo Therapeutics (1) Chia Tai Tianqing Pharmaceutical Group (1) BeiGene (1) Sun Yat-sen University (1) AstraZeneca (1) Eilean Therapeutics (1) Fudan University (1) Incyclix Bio (1)
CDK4 (5) CDK6 (4) CDK1 (2) CDK9 (2) CDK7 (1) FLT3 (1) CDK5 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.